Emergent BioSolutions Inc. (EBS) — Analyst outlook / Analyst consensus target is. Based on 15 analyst ratings, the consensus is bullish — 11 Buy, 3 Hold, 1 Sell.
The consensus price target is $51.50 (low: $38.00, high: $65.00), representing an upside of 494.7% from the current price $8.66.
Analysts estimate Earnings Per Share (EPS) of $-0.84 and revenue of $1.10B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-3.60 vs est $-0.84 (missed -330.3%). 2025: actual $0.98 vs est $2.05 (missed -52.2%). Analyst accuracy: 7%.
EBS Stock — 12-Month Price Forecast
$51.50
▲ +494.69% Upside
Average Price Target
Based on 15 Wall Street analysts offering 12-month price targets for Emergent BioSolutions Inc., the average price target is $51.50, with a high forecast of $65.00, and a low forecast of $38.00.
The average price target represents a +494.69% change from the last price of $8.66.
Highest Price Target
$65.00
Average Price Target
$51.50
Lowest Price Target
$38.00
EBS Analyst Ratings
Buy
Based on 15 analysts giving stock ratings to Emergent BioSolutions Inc. in the past 3 months
EPS Estimates — EBS
7%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$3.60
vs Est –$0.84
▼ 76.8% off
2025
Actual $0.98
vs Est $2.05
▼ 109.2% off
Profitability Outlook
Company has mixed profitability — some years profitable, some at a loss. EPS trend is improving.
Revenue Estimates — EBS
91%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $1.014B
vs Est $1.098B
▼ 8.4% off
2025
Actual $0.743B
vs Est $0.809B
▼ 9.0% off
Revenue Trend
Revenue has declined over the period shown. Analysts forecast significant revenue growth ahead.
